Bibliographic Details
| Title: |
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events |
| Authors: |
Remo Poto, Teresa Troiani, Gjada Criscuolo, Giancarlo Marone, Fortunato Ciardiello, Carlo Gabriele Tocchetti, Gilda Varricchi |
| Source: |
Frontiers in Immunology, Vol 13 (2022) |
| Publisher Information: |
Frontiers Media S.A., 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Immunologic diseases. Allergy |
| Subject Terms: |
cancer, cytotoxic T lymphocyte-associated protein (CTLA-4), immunotherapy, immune checkpoint inhibitor (ICI), immune-related adverse event (irAE), programmed cell death protein -1 (PD-1), Immunologic diseases. Allergy, RC581-607 |
| More Details: |
Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its ligand, programmed cell death protein ligand 1 (PD-L1) and enhance antitumor T-cell activity. ICIs provide clinical benefits in a percentage of patients with advanced cancers, but they are usually associated with a remarkable spectrum of immune-related adverse events (irAEs) (e.g., rash, colitis, hepatitis, pneumonitis, endocrine, cardiac and musculoskeletal dysfunctions). Particularly patients on combination therapy (e.g., anti-CTLA-4 plus anti-PD-1/PD-L1) experience some form of irAEs. Different mechanisms have been postulated to explain these adverse events. Host factors such as genotype, gut microbiome and pre-existing autoimmune disorders may affect the risk of adverse events. Fatal ICI-related irAEs are due to myocarditis, colitis or pneumonitis. irAEs usually occur within the first months after ICI initiation but can develop as early as after the first dose to years after ICI initiation. Most irAEs resolve pharmacologically, but some appear to be persistent. Glucocorticoids represent the mainstay of management of irAEs, but other immunosuppressive drugs can be used to mitigate refractory irAEs. In the absence of specific trials, several guidelines, based on data from retrospective studies and expert consensus, have been published to guide the management of ICI-related irAEs. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1664-3224 |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fimmu.2022.804597/full; https://doaj.org/toc/1664-3224 |
| DOI: |
10.3389/fimmu.2022.804597 |
| Access URL: |
https://doaj.org/article/57ec00b212e745f49afa86a3d1931f21 |
| Accession Number: |
edsdoj.57ec00b212e745f49afa86a3d1931f21 |
| Database: |
Directory of Open Access Journals |
